Industry bodies and private partners moved to tackle cell and gene manufacturing constraints with new standards and collaborative R&D. USP released standards aimed at viral vectors (starting with plasmid DNA and AAV empty‑full measurements) to harmonize quality metrics across the field. Separately, Bracco Imaging and Limula announced an Innosuisse‑funded collaboration with University of Fribourg researchers to combine lipid‑microbubble selection and automated cell processing as an alternative to magnetic‑bead cell selection. Both actions address reproducibility and scalability—USP by publishing measurable best practices and reference standards; the Bracco/Limula partnership by testing novel hardware and microbubble‑based affinity approaches to improve cell selection, activation and throughput for T‑cell and other cell therapies.